Pyrhönen S, Laasonen A, Tammilehto L, Rautonen J, Anttila S, Mattson K, Holsti L R
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Eur J Cancer. 1991;27(2):197-200. doi: 10.1016/0277-5379(91)90487-x.
70 histologically verified, malignant mesotheliomas were analysed by flow cytometry for DNA content and S-phase fraction (SPF) of tumour cells. 60% (42/70) were DNA diploid. 18 of the 28 aneuploid tumours were near-diploid with DNA indices of 1.3 or less. SPF could be calculated in 51 cases. SPF was significantly higher in aneuploid (median 16.0%) than in diploid tumours (median 5.6%). DNA ploidy was not a prognostic determinant; survival was the same for both aneuploid and diploid tumours. SPF, however, was significantly correlated (P = 0.039) with prognosis. Patients who had tumours with a low SPF survived almost twice as long as those with a high SPF. Thus malignant mesothelioma has a peculiar DNA ploidy pattern compared with many other solid tumours, with a predominance of diploid or near-diploid type cells. As in many other tumours, SPF may be used as a clinically relevant prognostic indicator.
对70例经组织学证实的恶性间皮瘤进行了流式细胞术分析，以检测肿瘤细胞的DNA含量和S期分数（SPF）。60%（42/70）为DNA二倍体。28例非整倍体肿瘤中有18例为近二倍体，DNA指数为1.3或更低。51例可计算SPF。非整倍体肿瘤的SPF（中位数16.0%）显著高于二倍体肿瘤（中位数5.6%）。DNA倍性不是一个预后决定因素；非整倍体和二倍体肿瘤的生存率相同。然而，SPF与预后显著相关（P = 0.039）。SPF低的肿瘤患者的生存期几乎是SPF高的患者的两倍。因此，与许多其他实体瘤相比，恶性间皮瘤具有独特的DNA倍性模式，以二倍体或近二倍体细胞为主。与许多其他肿瘤一样，SPF可作为一个具有临床相关性的预后指标。
